CN1857439A - Preparation and application of ginkgo leaf flavonid composition - Google Patents
Preparation and application of ginkgo leaf flavonid composition Download PDFInfo
- Publication number
- CN1857439A CN1857439A CN 200610046070 CN200610046070A CN1857439A CN 1857439 A CN1857439 A CN 1857439A CN 200610046070 CN200610046070 CN 200610046070 CN 200610046070 A CN200610046070 A CN 200610046070A CN 1857439 A CN1857439 A CN 1857439A
- Authority
- CN
- China
- Prior art keywords
- total
- total flavones
- content
- flavones
- flavone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 39
- 239000000203 mixture Substances 0.000 title claims abstract description 34
- BWWAFUZQSLIIIH-UHFFFAOYSA-N 2-phenyl-3H-chromen-3-id-4-one Chemical compound O1C(=[C-]C(=O)C2=CC=CC=C12)C1=CC=CC=C1 BWWAFUZQSLIIIH-UHFFFAOYSA-N 0.000 title claims abstract description 12
- 241000218628 Ginkgo Species 0.000 title claims description 56
- 235000011201 Ginkgo Nutrition 0.000 title claims description 56
- 235000008100 Ginkgo biloba Nutrition 0.000 title claims description 56
- 235000011949 flavones Nutrition 0.000 claims abstract description 105
- 229930003944 flavone Natural products 0.000 claims abstract description 102
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 claims abstract description 25
- 150000002212 flavone derivatives Chemical class 0.000 claims abstract description 25
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 claims abstract description 25
- 229930182490 saponin Natural products 0.000 claims abstract description 10
- 150000007949 saponins Chemical class 0.000 claims abstract description 10
- 239000003814 drug Substances 0.000 claims abstract description 9
- 201000010099 disease Diseases 0.000 claims abstract description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 7
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 5
- 206010039966 Senile dementia Diseases 0.000 claims abstract description 5
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims abstract 3
- 150000002213 flavones Chemical class 0.000 claims description 77
- 239000009636 Huang Qi Substances 0.000 claims description 16
- 235000003935 Hippophae Nutrition 0.000 claims description 14
- 241000229143 Hippophae Species 0.000 claims description 14
- 229930182470 glycoside Natural products 0.000 claims description 14
- 150000002338 glycosides Chemical class 0.000 claims description 14
- 241000628997 Flos Species 0.000 claims description 13
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims description 13
- 206010008118 cerebral infarction Diseases 0.000 claims description 9
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 9
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 235000017709 saponins Nutrition 0.000 claims description 8
- 201000006474 Brain Ischemia Diseases 0.000 claims description 7
- 206010008120 Cerebral ischaemia Diseases 0.000 claims description 7
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 6
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 229930182478 glucoside Natural products 0.000 claims description 3
- 150000008131 glucosides Chemical class 0.000 claims description 3
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 claims description 3
- 230000003712 anti-aging effect Effects 0.000 claims description 2
- 230000004064 dysfunction Effects 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims 3
- 238000010521 absorption reaction Methods 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 210000004877 mucosa Anatomy 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 235000003255 Carthamus tinctorius Nutrition 0.000 abstract description 3
- 244000020518 Carthamus tinctorius Species 0.000 abstract description 3
- 150000001875 compounds Chemical class 0.000 abstract description 3
- 244000194101 Ginkgo biloba Species 0.000 abstract 3
- 230000000747 cardiac effect Effects 0.000 abstract 2
- 230000002490 cerebral effect Effects 0.000 abstract 2
- 208000019553 vascular disease Diseases 0.000 abstract 2
- 241001061264 Astragalus Species 0.000 abstract 1
- 240000000950 Hippophae rhamnoides Species 0.000 abstract 1
- 235000003145 Hippophae rhamnoides Nutrition 0.000 abstract 1
- 241001412304 Ixeris Species 0.000 abstract 1
- 244000170916 Paeonia officinalis Species 0.000 abstract 1
- 235000006484 Paeonia officinalis Nutrition 0.000 abstract 1
- 241000219780 Pueraria Species 0.000 abstract 1
- 235000006533 astragalus Nutrition 0.000 abstract 1
- 210000004233 talus Anatomy 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 49
- 239000000843 powder Substances 0.000 description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 26
- 239000002775 capsule Substances 0.000 description 24
- 210000000582 semen Anatomy 0.000 description 15
- 239000008215 water for injection Substances 0.000 description 12
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 239000011347 resin Substances 0.000 description 8
- 229920005989 resin Polymers 0.000 description 8
- 239000002904 solvent Substances 0.000 description 7
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 229930195725 Mannitol Natural products 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 6
- 239000002671 adjuvant Substances 0.000 description 6
- 239000003963 antioxidant agent Substances 0.000 description 6
- 230000003078 antioxidant effect Effects 0.000 description 6
- 235000006708 antioxidants Nutrition 0.000 description 6
- 239000002738 chelating agent Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000000945 filler Substances 0.000 description 6
- 239000012467 final product Substances 0.000 description 6
- 239000008187 granular material Substances 0.000 description 6
- 239000000594 mannitol Substances 0.000 description 6
- 235000010355 mannitol Nutrition 0.000 description 6
- 239000008107 starch Substances 0.000 description 6
- 235000019698 starch Nutrition 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 238000005303 weighing Methods 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 5
- 235000019634 flavors Nutrition 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 4
- 239000003463 adsorbent Substances 0.000 description 4
- 230000032683 aging Effects 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 210000004165 myocardium Anatomy 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 238000007670 refining Methods 0.000 description 3
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 208000026139 Memory disease Diseases 0.000 description 2
- 239000004952 Polyamide Substances 0.000 description 2
- 241000219100 Rhamnaceae Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000005238 degreasing Methods 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 229920002647 polyamide Polymers 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- MQVRGDZCYDEQML-UHFFFAOYSA-N Astragalin Natural products C1=CC(OC)=CC=C1C1=C(OC2C(C(O)C(O)C(CO)O2)O)C(=O)C2=C(O)C=C(O)C=C2O1 MQVRGDZCYDEQML-UHFFFAOYSA-N 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- YKRGDOXKVOZESV-WRJNSLSBSA-N Paeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-WRJNSLSBSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 239000003218 coronary vasodilator agent Substances 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- JPUKWEQWGBDDQB-QSOFNFLRSA-N kaempferol 3-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=CC(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O JPUKWEQWGBDDQB-QSOFNFLRSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- 230000003680 myocardial damage Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to compound preparation with gingko leaf flavonid composition as main component for treating cardiac and cerebral vascular diseases. The gingko leaf flavonid composition contains gingko leaf flavonid in 1-99 wt%, and sowthistle-leaf ixeris flavonid and saponin, pueraria flavonid, safflower flavonid, total astragalus flavone and saponin, general peony glycosideor seabuckthorn flavonid in 1-99 wt%, and is compounded with pharmaceutically acceptable supplementary material to prepare pharmaceutically acceptable preparations. The medicine of the present invention is used in preventing and treating cardiac and cerebral vascular diseases, senile dementia, and other diseases.
Description
Technical field:
The present invention relates to a kind of compound preparation of the treatment cardiovascular and cerebrovascular disease based on ginkgo leaf flavonid composition.And the application of various preparations in pharmaceutical field that utilizes the inventive method to obtain, the particularly application in the medicine of preparation control cardiovascular and cerebrovascular disease, senile dementia, cerebral infarction, cerebral ischemia and other various diseases of causing by cerebral ischemia thereof etc.Make a distinction between the important and the lesser one in the full side of medicine of the present invention, compatibility is proper, and complementation is short mutually.
Background technology:
Semen Ginkgo, Herba Ixeritis Sonchifoliae, Radix Puerariae, Flos Carthami, the Radix Astragali, Radix Paeoniae Rubra, the Radix Paeoniae Alba, Fructus Hippophae etc. all are China's conventional Chinese medicines, and its medicine as the treatment cardiovascular and cerebrovascular disease has basis of clinical application widely and long clinical application history, and evident in efficacy.Modern pharmacology studies show that Folium Ginkgo total flavones and Herba Ixeritis Sonchifoliae total flavones have effects such as blood vessel dilating, blood flow increasing, blood viscosity lowering, quickening blood flow rate, anti-hypoxia; Radix Puerariae total flavones (its main component is a puerarin) has promoting blood circulation and stopping pain, expansion is normal and the coronary vasodilator of spasm, lax vascular smooth muscle, improve ischemic region the cardiac muscle power supply, reduce the myocardium lactic acid that causes because of ischemia generation, reduce oxygen consumption, improve effect such as myocardial metabolism; Flos Carthami total flavone has effects such as coronary artery dilator, coronary blood flow increasing, microcirculation improvement, blood fat reducing, blood pressure lowering; Radix Astragali total flavones and total saponins thereof have the myocardium shrinkage function of improvement, dwindle myocardial infarction area, alleviate myocardial damage, improve myocardial ischemia, protect effects such as cardiovascular and cerebrovascular vessel, microcirculation improvement, antiviral property myocarditis; Peoniflorin have promote learning memory disorder due to learning and memory, the antagonism scopolamine, significantly improve learning memory disorder due to the cerebral ischemia re-pouring, improve effects such as body microcirculating state, blood viscosity lowering, the inductive platelet aggregation of inhibition ADP.Modern clinical research shows that Fructus Hippophae total flavones has curative effect preferably for angina pectoris, coronary heart disease.
How to overcome the shortcoming of taking single medicinal material, reasonable compatibility, short complementary mutually, make it to become effective good recipe of treatment diseases of cardiovascular and cerebrovascular systems, making it to bring into play the best use of at aspect such as improve cardio-cerebrovascular function and control aging of brain, raise immunity, slow down aging, improve the quality of living is its maximum difficult point.
Summary of the invention:
The objective of the invention is defective and deficiency at above-mentioned prior art existence, provide a kind of and can overcome the shortcoming of taking single medicinal material, reasonable compatibility, short complementary mutually, make it to become effective good recipe of treatment diseases of cardiovascular and cerebrovascular systems, make it that the best use of is brought into play in the aspect improving cardio-cerebrovascular function and control aging of brain, raise immunity, slow down aging, improve the quality of living etc.
The compositions that further aim of the present invention provides Folium Ginkgo total flavones (is the compositions of Folium Ginkgo total flavones and Herba Ixeritis Sonchifoliae total flavones, the compositions of Folium Ginkgo total flavones and Radix Puerariae total flavones, Folium Ginkgo total flavones and total safflower flavone composition, Folium Ginkgo total flavones and Radix Astragali total flavones and total astragalin composition, the compositions of Folium Ginkgo total flavones and Radix Paeoniae Alba total glycosides, the compositions of Folium Ginkgo total flavones and Fructus Hippophae total flavones) and the application of preparation in pharmaceutical field, particularly be used to prevent and treat cardiovascular and cerebrovascular disease in preparation, senile dementia, other dysfunction that cerebral ischemia causes, the medicine of the anti-ageing disease of waiting for a long time.
The present invention is implemented by following technical proposals.
The present invention relates to a kind of is the method for the compound preparation of main preparation control cardiovascular and cerebrovascular disease, senile dementia, cerebral ischemia and other various diseases of being caused by cerebral ischemia thereof etc. by ginkgo leaf flavonid composition, it is characterized in that this method comprises following content:
(1) calculates according to composition by weight and get 1～99 part of Folium Ginkgo total flavones (content of total flavone is 20%～100% in the Folium Ginkgo total flavones) and Radix Puerariae total flavones respectively (content of total flavone is 20%～100% in the Radix Puerariae total flavones, comprise that also content reaches the puerarin more than 90%) 99～1 parts, respectively or mix the back and add suitable adjuvant such as antioxidant, chelating agent, filler, framework material etc. and make said various preparations on any pharmaceutics.As be used for can be made into forms such as corresponding tablet, granule, capsule when oral; Make powder pin, freeze-dried powder, transfusion etc. when being used to inject.
(2) calculate according to composition by weight and get 99～1 parts of 1～99 part of Folium Ginkgo total flavones (content of total flavone is 20%～100% in the Folium Ginkgo total flavones) and Herba Ixeritis Sonchifoliae total flavoness (content of total flavone is 20%～100% in the Herba Ixeritis Sonchifoliae total flavones) respectively, respectively or mix the suitable adjuvant of back adding such as antioxidant, chelating agent, filler, framework material etc. and make said various preparations on any pharmaceutics.As be used for can be made into forms such as corresponding tablet, granule, capsule when oral; Make powder pin, freeze-dried powder, transfusion etc. when being used to inject.
(3) calculate according to composition by weight and get 99～1 parts of 1～99 part of and Flos Carthami total flavones of Folium Ginkgo total flavones (content of total flavone is 20%～100% in the Folium Ginkgo total flavones) (content of total flavone is 20%～100% in the total flavones) respectively, respectively or mix the back and add suitable adjuvant such as antioxidant, chelating agent, filler, framework material etc. and make said various preparations on any pharmaceutics.As be used for can be made into forms such as corresponding tablet, granule, capsule when oral; Make powder pin, freeze-dried powder, transfusion etc. when being used to inject.
(4) calculate according to composition by weight and get 1～99 part of Folium Ginkgo total flavones (content of total flavone is 20%～100% in the Folium Ginkgo total flavones) and Radix Astragali total flavones and total saponins respectively (content of total flavone is 20%～90% in the Radix Astragali total flavones, the content of total saponins is 10%～90%) 99～1 parts, respectively or mix the back and add suitable adjuvant such as antioxidant, chelating agent, filler, framework material etc. and make said various preparations on any pharmaceutics.As be used for can be made into forms such as corresponding tablet, granule, capsule when oral; Make powder pin, freeze-dried powder, transfusion etc. when being used to inject.
(5) calculate according to composition by weight and get 1～99 part of Folium Ginkgo total flavones (content of total flavone is 20%～100% in the Folium Ginkgo total flavones) respectively and Radix Paeoniae Alba total glycosides (comprises Radix Paeoniae Rubra total glycosides and Radix Paeoniae Alba total glucosides, wherein the content of Radix Paeoniae Alba total glycosides is 20%～100%) 99～1 parts, respectively or mix the back and add suitable adjuvant such as antioxidant, chelating agent, filler, framework material etc. and make said various preparations on any pharmaceutics.As be used for can be made into forms such as corresponding tablet, granule, capsule when oral; Make powder pin, freeze-dried powder, transfusion etc. when being used to inject.
(6) calculate according to composition by weight and get 99～1 parts of 1～99 part of Folium Ginkgo total flavones (content of total flavone is 20%～100% in the Folium Ginkgo total flavones) and Fructus Hippophae total flavoness (content of total flavone is 20%～100% in the Fructus Hippophae total flavones) respectively, respectively or mix the suitable adjuvant of back adding such as antioxidant, chelating agent, filler, framework material etc. and make said various preparations on any pharmaceutics.As be used for can be made into forms such as corresponding tablet, granule, capsule when oral; Make powder pin, freeze-dried powder, transfusion etc. when being used to inject.
The specific embodiment
The following examples can help those skilled in the art more fully to understand the present invention.But do not limit the present invention in any way.
Embodiment 1 Semen Ginkgo Radix Puerariae freeze-dried powder
Get Radix Puerariae total flavones 1.5g respectively, Folium Ginkgo total flavones 2.0g mixes the back with an amount of water for injection dissolving, adds 16g mannitol, after the dissolving, be diluted to 200ml, filter with water for injection, fill, lyophilizing adopts conventional injectable powder preparation method can obtain 100 freeze-dried powders.
Embodiment 2 Semen Ginkgo Ixers sonchifolia freeze-dried powders
Get Folium Ginkgo total flavones 1.0g respectively, Herba Ixeritis Sonchifoliae total flavones 2.5g mixes the back with an amount of water for injection dissolving, adds 16g mannitol, after the dissolving, be diluted to 200ml, filter with water for injection, fill, lyophilizing adopts conventional injectable powder preparation method can obtain 100 freeze-dried powders.
Embodiment 3 Semen Ginkgo Radix Paeoniae freeze-dried powders
Get Folium Ginkgo total flavones 1.8g respectively, Radix Paeoniae Alba total glycosides 3.0g mixes the back with an amount of water for injection dissolving, adds 16g mannitol, after the dissolving, be diluted to 200ml, filter with water for injection, fill, lyophilizing adopts conventional injectable powder preparation method can obtain 100 freeze-dried powders.
Embodiment 4 Semen Ginkgo Flos Carthami freeze-dried powders
Get Folium Ginkgo total flavones 2.5g respectively, Flos Carthami total flavone 1.5g mixes the back with an amount of water for injection dissolving, adds 16g mannitol, after the dissolving, be diluted to 200ml, filter with water for injection, fill, lyophilizing adopts conventional injectable powder preparation method can obtain 100 freeze-dried powders.
Embodiment 5 Semen Ginkgo Radix Astragali freeze-dried powders
Get Folium Ginkgo total flavones 2.5g respectively, Radix Astragali total flavones 2.0g mixes the back with an amount of water for injection dissolving, adds 16g mannitol, after the dissolving, be diluted to 200ml, filter with water for injection, fill, lyophilizing adopts conventional injectable powder preparation method can obtain 100 freeze-dried powders.
Embodiment 6 ginkgo-sea buckthorn freeze-dried powders
Get Folium Ginkgo total flavones 2.5g respectively, Fructus Hippophae total flavones 1.0g mixes the back with an amount of water for injection dissolving, adds 16g mannitol, after the dissolving, be diluted to 200ml, filter with water for injection, fill, lyophilizing adopts conventional injectable powder preparation method can obtain 100 freeze-dried powders.
Embodiment 7 Semen Ginkgo radix puerariae capsules
Get Radix Puerariae total flavones 25g respectively, Folium Ginkgo total flavones 30g, starch 150g adopts conventional capsule preparation method thereof can make 1000 capsules after mixing.
Embodiment 8 Semen Ginkgo Herba Ixeritis Sonchifoliae capsules
Get Folium Ginkgo total flavones 10g respectively, Herba Ixeritis Sonchifoliae total flavones 25g, starch 150g adopts conventional capsule preparation method thereof can make 1000 capsules after mixing.
Embodiment 9 Semen Ginkgo Radix Paeoniae capsules
Get Folium Ginkgo total flavones 15g respectively, Radix Paeoniae Alba total glycosides 35g, starch 150g adopts conventional capsule preparation method thereof can make 1000 capsules after mixing.
Embodiment 10 Semen Ginkgo safflower capsules
Get Folium Ginkgo total flavones 20g respectively, Flos Carthami total flavone 10g, starch 150g adopts conventional capsule preparation method thereof can make 1000 capsules after mixing.
Embodiment 11 Semen Ginkgo Radix Astragali capsules
Get Folium Ginkgo total flavones 15g respectively, Radix Astragali total flavones 25g, starch 150g adopts conventional capsule preparation method thereof can make 1000 capsules after mixing.
Embodiment 12 ginkgo-sea buckthorn capsules
Get Folium Ginkgo total flavones 20g respectively, Fructus Hippophae total flavones 20g, starch 150g adopts conventional capsule preparation method thereof can make 1000 capsules after mixing.
The extraction of embodiment 13 Folium Ginkgo total flavoness, Herba Ixeritis Sonchifoliae total flavones, Flos Carthami total flavone, Radix Puerariae total flavones, Fructus Hippophae total flavones, Radix Astragali total flavones
(1) takes by weighing Semen Ginkgo stem and leaf or Herba Ixeritis Sonchifoliae or Flos Carthami or Radix Puerariae or Fructus Hippophae or Radix Astragali 1Kg, water or variable concentrations alcohol (comprising ethanol, methanol etc.) extract 1～3 time, and (the solvent consumption is 15Kg～30Kg), be evaporated to 0.5～1L, adds 1～4L ethanol, filter, reclaim ethanol to there not being the alcohol flavor.Concentrate with suitable quantity of water dissolving (100～1000ml), with organic solvent degreasing (comprise petroleum ether, chloroform, etc., hyposynchronization also can save), extractions such as ethyl acetate or n-butyl alcohol or n-amyl alcohol, get final product behind the recovery organic solvent the total flavones crude product.
(2) take by weighing Semen Ginkgo stem and leaf or Herba Ixeritis Sonchifoliae or Flos Carthami or Radix Puerariae or Fructus Hippophae or Radix Astragali 1Kg, add 6～10 times of water gagings, regulate pH to 8～9, decocted 0.5～3 hour, filter, extract so repeatedly 1～3 time with lime cream.Merge extractive liquid, is chilled to below 70 ℃, regulates pH to 3～5 with acid (comprising mineral acid and organic acid such as acetic acid, trichloroacetic acid such as hydrochloric acid, sulphuric acid), and is static, filter get final product the total flavones crude product.
(3) take by weighing Semen Ginkgo stem and leaf or Herba Ixeritis Sonchifoliae or Flos Carthami or Radix Puerariae or Fructus Hippophae or Radix Astragali 1Kg, water or different concentration ethanol are extracted 1～3 time (the solvent consumption are 15Kg～30Kg), be evaporated to 0.5～1L, adds 1～4L ethanol, filters, and reclaims ethanol to there not being the alcohol flavor.With suitable quantity of water dissolving (100～1000ml), (comprise polarity, middle polarity and nonpolar macroporous adsorption resin through the separation of macroporous adsorbent resin chromatography post, the ratio of the consumption of resin and crude drug is 1: 0.2～5), water, different concentration ethanol or methanol-eluted fractions successively, collect different concentration ethanol or methanol-eluted fractions fraction, reclaim get final product behind the solvent the different total flavones elaboration of purity.The total flavones crude product that obtains in above-mentioned (1 and 2) also can be by macroporous adsorbent resin chromatography post refining (method be the same).
(4) take by weighing Semen Ginkgo stem and leaf or Herba Ixeritis Sonchifoliae or Flos Carthami or Radix Puerariae or Fructus Hippophae or Radix Astragali 1Kg, water or different concentration ethanol are extracted 1～3 time (the solvent consumption are 15Kg～30Kg), be evaporated to 0.5～1L, adds 1～4L ethanol, filters, and reclaims ethanol to there not being the alcohol flavor.With suitable quantity of water dissolving (100～1000ml), separate through the polyamide chromatographic column, water, different concentration ethanol or methanol-eluted fractions are collected different concentration ethanol or methanol-eluted fractions fraction successively, reclaim get final product behind the solvent the different total flavones elaboration of purity.The total flavones crude product that obtains in above-mentioned (1 and 2) also can be by polyamide chromatographic column refining (method be the same).
The extraction of embodiment 14 Radix Paeoniae Alba total glycosides
(1) take by weighing Radix Paeoniae 1Kg, water or variable concentrations alcohol (comprising ethanol, methanol etc.) extract 1～3 time (the solvent consumption are 15Kg～30Kg), be evaporated to 0.5～1L, adds 1～4L ethanol, filters, and reclaims ethanol to there not being the alcohol flavor.Concentrate with suitable quantity of water dissolving (100～1000ml), with organic solvent degreasing (comprise petroleum ether, chloroform, ethyl acetate etc., hyposynchronization also can save), n-butanol extraction (comprising n-amyl alcohol etc.), reclaim get final product behind the n-butyl alcohol total glycosides slightly.
(2) take by weighing Radix Paeoniae 1Kg, water or different concentration ethanol are extracted 1～3 time (the solvent consumption are 15Kg～30Kg), be evaporated to 0.5～1L, adds 1～4L ethanol, filters, and reclaims ethanol to there not being the alcohol flavor.With suitable quantity of water dissolving (100～1000ml), (comprise polarity, middle polarity and nonpolar macroporous adsorption resin through the separation of macroporous adsorbent resin chromatography post, the ratio of the consumption of resin and crude drug is 1: 0.2～5), water, different concentration ethanol eluting successively, collect the different concentration ethanol eluting fraction, get final product the different total glycosides elaboration of purity.The thick total saponins that obtains in above-mentioned (1) also can be by macroporous adsorbent resin chromatography post refining (method be the same).
Claims (9)
1, a kind of ginkgo leaf flavonid composition, it is characterized in that being grouped into (percentage by weight): Folium Ginkgo total flavones 1%～99%, Herba Ixeritis Sonchifoliae total flavones and saponin 99%～1% or Radix Puerariae total flavones 99%～1% or Flos Carthami total flavone 99%～1% or Radix Astragali total flavones and total saponins 99%～1% or Radix Paeoniae Alba total glycosides (comprising Radix Paeoniae Rubra total glycosides and Radix Paeoniae Alba total glucosides) 99%～1% or Fructus Hippophae total flavones 99%～1% by following one-tenth.More particularly, be meant in Folium Ginkgo total flavones and the said medicine combination of any one or two or more medicines, be equipped with suitable pharmaceutic adjuvant, make the pharmaceutically various preparations of acceptable.
2, according to right 1 described preparation, it is characterized in that: content of total flavone is 20%～100% in the Folium Ginkgo total flavones in the described composition.
3, according to right 1 described preparation, it is characterized in that: content of total flavone is 20%～100% in the Herba Ixeritis Sonchifoliae total flavones in the described composition.
4, according to right 1 described preparation, it is characterized in that: content of total flavone is 20%～100% in the Radix Puerariae total flavones in the described composition, comprises that also content reaches the puerarin more than 90%.
5, according to right 1 described preparation, it is characterized in that: content of total flavone is 20%～100% in the Flos Carthami total flavone in the described composition; Content of total flavone is 20%～90% in Radix Astragali total flavones and the total saponins, and the content of total saponins is 10%～90%; The content of the Radix Paeoniae Alba total glycosides in the Radix Paeoniae Alba total glycosides (comprising Radix Paeoniae Rubra total glycosides and Radix Paeoniae Alba total glucosides) is 20%～100%.
6, according to right 1 described preparation, it is characterized in that: content of total flavone is 20%～100% in the Fructus Hippophae total flavones in the described composition.
7, according to right 1 described preparation of compositions method, it is characterized in that: it is the characteristics according to various compositionss, and the modern preparation technique that allows on the employing pharmaceutics is realized.
8, all kinds of preparations of making according to right 1 described compositions, it is characterized in that: it comprises injection type, peroral dosage form, percutaneous dosing dosage form, mucosa absorption dosage form.
9, all kinds of preparations of making according to right 1 described compositions is characterized in that: be mainly used in other dysfunction, the anti-ageing disease of waiting for a long time that control cardiovascular and cerebrovascular disease, senile dementia, cerebral infarction, cerebral ischemia cause.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200610046070 CN1857439A (en) | 2006-03-17 | 2006-03-17 | Preparation and application of ginkgo leaf flavonid composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200610046070 CN1857439A (en) | 2006-03-17 | 2006-03-17 | Preparation and application of ginkgo leaf flavonid composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1857439A true CN1857439A (en) | 2006-11-08 |
Family
ID=37296427
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200610046070 Pending CN1857439A (en) | 2006-03-17 | 2006-03-17 | Preparation and application of ginkgo leaf flavonid composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1857439A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101703535B (en) * | 2009-11-05 | 2011-05-04 | 浙江大学 | Method for improving content of drug efficacy components of ginkgo leaf |
-
2006
- 2006-03-17 CN CN 200610046070 patent/CN1857439A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101703535B (en) * | 2009-11-05 | 2011-05-04 | 浙江大学 | Method for improving content of drug efficacy components of ginkgo leaf |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1857473A (en) | Gynostemma pentaphylla saponin composition preparation and its preparing process | |
| CN1857388A (en) | Preparation and application of notoginseng stem and leaf total saponin composition | |
| CN1857472A (en) | Ginsenoside composition preparation and its preparing process | |
| CN101700289B (en) | Traditional Chinese medicine extract composition for treating gastrointestinal dysfunction or irritable bowel syndrome (IBS), and preparation method and applications thereof in preparation of medicaments | |
| CN1857441A (en) | Preparation and application of total salvianolic acid composition | |
| CN102134268B (en) | Method for preparing panax japonicus saponin IVa and application of panax japonicus saponin IVa in preparing a medicament for protecting liver and lowering transaminase | |
| CN100534508C (en) | Method for extracting effective sites group of smilax China root | |
| CN1229324C (en) | Extraction process of tanshin general phenolic acid and its prepn and use | |
| CN102362971B (en) | A kind of preparation method and preparation for the treatment of coronary heart disease Chinese medicine and effective chemical constituent thereof | |
| CN101991567A (en) | Application of three biflavone monomer components extracted from ginkgo leaves in preparing medicament of alpha-glucosidase inhibitor | |
| CN1857377A (en) | Preparation and application of total safflower flavone composition | |
| CN1857442A (en) | Preparation and application of ligustrazine and its salt composition | |
| CN1857469A (en) | Arasaponin composition preparation and its preparing process | |
| CN101119740B (en) | Use of radix sanguisorbae and its extract for preparing medicament to increase RBC and hemoglobin | |
| CN1857439A (en) | Preparation and application of ginkgo leaf flavonid composition | |
| CN1857395A (en) | Compound Chinese medicine composition for treating cardiac and cerebral vascular diseases | |
| CN100569240C (en) | Pharmaceutical uses of hesperidin and/or naringin | |
| CN105640970B (en) | Effective part of ginseng stem and leaf and preparation method and application thereof | |
| CN1857468A (en) | Prepn and application of haw heaf total phenolic acid composition | |
| CN1857471A (en) | Tribuloside composition preparing and its preparing process | |
| CN1814149A (en) | Medicine composition for treating diabetes or diabetes kidney-disease, and preparing method | |
| CN1857387A (en) | Preparation and application of pueraria flavonid composition | |
| CN100479837C (en) | Weinakang for treating ischemic cerebrovascular disease and senile dementia and preparation method thereof | |
| CN1857470A (en) | Preparation and application of shortscape fleabane herb flavonid composition | |
| CN1857443A (en) | Preparation and application of astragalus flavonid and total astragalin composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |